Evidence map›Paper›PMID 35618787›Full record

ArticleBritish journal of cancer2022

Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).

Usha Menon, David Weller, Alina Zalounina Falborg, Henry Jensen, John Butler, Andriana Barisic, Anne Kari Knudsen, Rebecca J Bergin, David H Brewster, Victoria Cairnduff and 15 more

Abstract read
In one paragraph

Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Ovarian cancer presentation and management in sub-Saharan Africa: a scooping review protocal.Malawi medical journal : the journal of Medical Association of Malawi · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK. u.menon@ucl.ac.uk.ORCID http://orcid.org/0000-0003-3708-1732
David WellerCentre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
Alina Zalounina FalborgResearch Unit for General Practice, Aarhus, Denmark.ORCID http://orcid.org/0000-0002-1616-9455
Henry JensenResearch Unit for General Practice, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4040-7334
John ButlerThe Royal Marsden NHS Foundation Trust, London, UK.
Andriana BarisicOntario Health (Cancer Care Ontario), Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-3939-5129
Anne Kari KnudsenEuropean Palliative Care Research Centre (PRC), Department of Oncology, Oslo, Norway.
Rebecca J BerginCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
David H BrewsterCentre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
Victoria CairnduffNorthern Ireland Cancer Registry, Queen's University Belfast, Belfast, UK.
Evangelia Ourania FourkalaGynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London, London, UK.
Anna T GavinNorthern Ireland Cancer Registry, Queen's University Belfast, Belfast, UK.
Eva GrunfeldHealth Services Research Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Elizabeth HarlandDepartment of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Canada.
Jatinderpal KalsiGynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London, London, UK.
Rebecca-Jane LawNorth Wales Centre for Primary Care Research, Bangor University, Wrexham, UK.
Yulan LinEuropean Palliative Care Research Centre (PRC), Department of Oncology, Oslo, Norway.
Donna TurnerPopulation Oncology, Cancer Care Manitoba, Winnipeg, Canada.
Richard D NealLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Victoria WhiteSchool of Psychology Deakin University, Geelong, VIC, Australia.
Samantha HarrisonInternational Cancer Benchmarking Partnership, Cancer Research UK, Stratford, UK.
Irene ReguilonInternational Cancer Benchmarking Partnership, Cancer Research UK, Stratford, UK.
Charlotte LynchInternational Cancer Benchmarking Partnership, Cancer Research UK, Stratford, UK.
Peter VedstedInternational Cancer Benchmarking Partnership, Cancer Research UK, Stratford, UK.ORCID http://orcid.org/0000-0003-2113-5599
ICBP Module 4 Working Group

Funding

Medical Research Council MC_UU_00004/02Medical Research Council MC_UU_12023/28
6 · The paper itself

Abstract

backgroundInternational Cancer Benchmarking Partnership Module 4 reports the first international comparison of ovarian cancer (OC) diagnosis routes and intervals (symptom onset to treatment start), which may inform previously reported variations in survival and stage.

methodsData were collated from 1110 newly diagnosed OC patients aged >40 surveyed between 2013 and 2015 across five countries (51-272 per jurisdiction), their primary-care physicians (PCPs) and cancer treatment specialists, supplement by treatment records or clinical databases. Diagnosis routes and time interval differences using quantile regression with reference to Denmark (largest survey response) were calculated.

resultsThere were no significant jurisdictional differences in the proportion diagnosed with symptoms on the Goff Symptom Index (53%; P = 0.179) or National Institute for Health and Care Excellence NG12 guidelines (62%; P = 0.946). Though the main diagnosis route consistently involved primary-care presentation (63-86%; P = 0.068), onward urgent referral rates varied significantly (29-79%; P < 0.001). In most jurisdictions, diagnostic intervals were generally shorter and other intervals, in particular, treatment longer compared to Denmark.

conclusionThis study highlights key intervals in the diagnostic pathway where improvements could be made. It provides the opportunity to consider the systems and approaches across different jurisdictions that might allow for more timely ovarian cancer diagnosis and treatment.

Indexed as

BenchmarkingOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansPrimary Health CareReferral and Consultation

Identifiers

PMID35618787
PMCPMC9427750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.